GBT - グロ―バル・ブラッド・セラピュ―ティクス （Global Blood Therapeutics Inc.） グロ―バル・ブラッド・セラピュ―ティクスGBTのチャート
GBTの企業情報
| symbol | GBT |
|---|---|
| 会社名 | Global Blood Therapeutics Inc （グロ―バル・ブラッド・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 グローバル・ブラッド・セラピューティクス（Global Blood Therapeutics Inc.）は臨床段階のバイオ医薬品会社である。同社は、血液ベースの障害を治療するための治療薬の発見・開発・商業化に従事する。同社は鎌状赤血球症（SCD）の経口一日1回治療薬として、初期製品候補であるGBT440を開発している。同社は成人および青年期のSCD患者のGBT440の第III相臨床試験において、SCDのGBT440を評価する。GBT440は、RBC鎌状赤血球の根底にある機構である異常なヘモグロビン重合を阻害する。また、遺伝性血管浮腫（HAE）を対象としたその他の研究開発活動を行う。GBT440は、ヘモグロビンのアルファ鎖に結合することにより、ヘモグロビンの酸素に対する親和性を増加させる治験薬である。GBT440は鎌状赤血球ヘモグロビン（HbS）を酸素化状態で保持し、重合に関与しないことが観察されている。 グロ―バル・ブラッド・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、血液疾患に関する医薬品の発見、開発、商業化に従事する。薬剤候補に鎌状赤血球病(SCD)予防薬「GBT440」があり、1日1回の経口投与で治療する。激痛や多臓器損傷をもたらすSCDに焦点を当て、赤血球のメカニズムを考慮した治療薬を開発する。本社はカリフォルニア州。 Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD. |
| 本社所在地 | 171 Oyster Point Boulevard Suite 300 South San Francisco CA 94080 USA |
| 代表者氏名 | Ted W. Love テッド・W・ラブ |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-741-7700 |
| 設立年月日 | 40575 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 148人 |
| url | www.globalbloodtx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/gbt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -153.88500 |
| 終値（lastsale） | 35.5 |
| 時価総額（marketcap） | 1847891937 |
| 時価総額 | 時価総額（百万ドル） 1968.135 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1505.651 |
| 当期純利益 | 当期純利益（百万ドル） -151.73300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Global Blood Therapeutics Inc revenues was not reported. Net loss increased 74% to $81.9M. Higher net loss reflects Research and Development Expense increase of 66% to $54.8M (expense) Stock-based Compensation in SGA increase from $2.7M to $8.8M (expense) General and administrative increase of 50% to $14.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.15 to -$1.65. |
GBTのテクニカル分析
GBTのニュース
Pfizer Completes Acquisition of Global Blood Therapeutics 2022/10/05 13:02:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities starting with sickle cell disease (SCD). The acquisition reinforces Pfizer’s commitment to SCD, building on a 30-year legacy in the rare hematology space. GBT brings a portfolio and pipeline tha
Global Blood Therapeutics expects to complete Pfizer deal by early October 2022/09/30 20:34:59 Seeking Alpha
Global Blood Therapeutics (GBT) expects to consummate its $5.4B deal with Pfizer (PFE) on Oct. 5, the sickle cell disease drugmaker said in a regulatory filing on Friday
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals 2022/09/16 16:41:57 Seeking Alpha
Global Blood Therapeutics has several intriguing molecules that could garner blockbuster sales for Pfizer in the coming years. Read what investors need to know.
Analysts Predicting A Spike In Global Blood Therapeutics Inc. (NASDAQ: GBT)? 2022/09/09 16:00:00 Stocks Register
Global Blood Therapeutics Inc. (NASDAQ:GBT) price on Friday, September 09, fall -0.01% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $67.97. A look at the stock’s price movement, the level at last check in today’s session was $67.98, moving within a range at $67.70 and $67.99. The … Analysts Predicting A Spike In Global Blood Therapeutics Inc. (NASDAQ: GBT)? Read More »
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, CVET, GBT, and MSTR Shareholders About Its Ongoing Investigations 2022/09/02 19:31:00 Kwhen Finance
Pfizer Completes Acquisition of Global Blood Therapeutics 2022/10/05 13:02:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities starting with sickle cell disease (SCD). The acquisition reinforces Pfizer’s commitment to SCD, building on a 30-year legacy in the rare hematology space. GBT brings a portfolio and pipeline tha
Global Blood Therapeutics expects to complete Pfizer deal by early October 2022/09/30 20:34:59 Seeking Alpha
Global Blood Therapeutics (GBT) expects to consummate its $5.4B deal with Pfizer (PFE) on Oct. 5, the sickle cell disease drugmaker said in a regulatory filing on Friday
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals 2022/09/16 16:41:57 Seeking Alpha
Global Blood Therapeutics has several intriguing molecules that could garner blockbuster sales for Pfizer in the coming years. Read what investors need to know.
Analysts Predicting A Spike In Global Blood Therapeutics Inc. (NASDAQ: GBT)? 2022/09/09 16:00:00 Stocks Register
Global Blood Therapeutics Inc. (NASDAQ:GBT) price on Friday, September 09, fall -0.01% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $67.97. A look at the stock’s price movement, the level at last check in today’s session was $67.98, moving within a range at $67.70 and $67.99. The … Analysts Predicting A Spike In Global Blood Therapeutics Inc. (NASDAQ: GBT)? Read More »
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, CVET, GBT, and MSTR Shareholders About Its Ongoing Investigations 2022/09/02 19:31:00 Kwhen Finance
What 4 Analyst Ratings Have To Say About Global Blood Therapeutics 2022/02/28 15:21:45 Benzinga
Global Blood Therapeutics (NASDAQ: GBT ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 These 4 analysts have an average price target of $56.5 versus the current price of Global Blood Therapeutics at $29.15, implying upside. Below is a summary of how these 4 analysts rated Global Blood Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive … Full story available on Benzinga.com
GBT Announces Participation in Upcoming Investor Conferences 2022/02/28 13:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences:
Global Blood Therapeutics (GBT) Q4 2021 Earnings Call Transcript 2022/02/24 05:30:40 The Motley Fool
GBT earnings call for the period ending December 31, 2021.
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q4 2021 Results - Earnings Call Transcript 2022/02/24 02:41:06 Seeking Alpha
Global Blood Therapeutics GAAP EPS of -$1.36 misses by $0.23, revenue of $56.1M beats by $0.65M 2022/02/23 21:08:00 Seeking Alpha
Global Blood Therapeutics press release (GBT): Q4 GAAP EPS of -$1.36 misses by $0.23.Revenue of $56.1M (+35.8% Y/Y) beats by $0.65M.Cash, cash equivalents, and marketable…